Figure 1 outlines the overall motivation and analytical strategy of our approach. In contrast to former strategies, our approach relies on the integration of an established CML population dynamic model with two patient-derived genomic biomarkers: firstly, a biopsy genome-wide expression-derived CD34+ similarity score as indicator of disease history and progression risk; and secondly, gene expression entropy as indicator of instability during critical states (Fig. 1b). Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.